NICE Endorses Brainomix AI-Enabled Software in Stroke finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
An artificial intelligence (AI)-powered tool from UK-based Brainomix was one of only two products to be endorsed by health assessor the National Institute of Health and Care Excellence (NICE).
Brainomix has partnered with the TIPAL trial group to run a sub-study that will assess the value of its e-Lung platform, an AI-powered image processing module. The TIPAL trial, a placebo-controlled, 52 week multi-centre study, is evaluating the impact of lansoprazole, a medication for treating indigestion, heartburn and acid reflux, on patients with idiopathic pulmonary fibrosis (IPF). Brainomix will be running a sub-study alongside the main study, to look at the value of its novel imaging biomarkers. The company's technology includes a tool that standardises the quantification of lung fibrosis on high resolution CT scans in order to more accurately identify progressive fibrosis patients. The AI platform uses a novel imaging biomarker, the weighted reticulovascular (WRV) score, to quantify the extent of the lung impacted by reticulovascular abnormalities. The aim of the sub-study is to determine the difference in change between baseline and 12 months post-randomisation, in WRV sco
A new report provides valuable insights into how NHS Hospitals are using an AI platform for stroke imaging and monitoring for stroke care and treatment.